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Abstract
The purpose of our study was to determine whether
the dual inhibition of epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor recep-
tor (VEGFR) signaling pathways in tumor-associated
endothelial cells can inhibit the progressive growth of
human colon carcinoma in the cecum of nude mice.
SW620CE2 human colon cancer cells growing in cul-
ture and orthotopically in the cecum of nude mice
expressed a high level of transforming growth factor
alpha (TGF-A) and vascular endothelial growth factor
(VEGF) but were negative for EGFR, human epidermal
growth factor receptor 2 (HER2), and VEGFR. Dou-
ble immunofluorescence staining revealed that tumor-
associated endothelial cells expressed EGFR, VEGFR2,
phosphorylated EGFR (pEGFR), and phosphorylated
VEGFR (pVEGFR). Treatment of mice with either 7H-
pyrrolo [2,3-d ]-pyrimidine lead scaffold (AEE788; an in-
hibitor of EGFR and VEGFR tyrosine kinase) or CPT-11
as single agents significantly inhibited the growth of
cecal tumors (P < .01); this decrease was even more
pronounced with AEE788 combined with CPT-11 (P <
.001). AEE788 alone or combined with CPT-11 also
inhibited the expression of pEGFR and pVEGFR on
tumor-associated endothelial cells, significantly de-
creased vascularization and tumor cell proliferation,
and increased the level of apoptosis in both tumor-
associated endothelial cells and tumor cells. These data
demonstrate that targeting EGFR and VEGFR signaling
on tumor-associated endothelial cells provides a viable
approach for the treatment of colon cancer.
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Introduction
Colorectal carcinoma is the third most common cancer
found in men and women in the United States and is re-
sponsible for the deaths of > 55,000 patients annually [1].
Despite the use of aggressive surgical resection and che-
motherapy, nearly 50% of patients with colorectal carcinoma
develop recurrent disease [2]. To foster the development of
new approaches to therapy, a better understanding of the
biology of colon cancer is critical. Because the genetic insta-
bility and biologic heterogeneity of neoplasms are the principal
causes of the failure of systemic antitumor therapy, targeting
the neovasculature of tumors has been explored as a way of
attacking a more genetically stable and essential component of
tumors [3,4].
Growth factors and their receptors play a pivotal role in the
regulation of cancer progression and neovascularization [5,6].
In particular, epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor receptor (VEGFR) have
been extensively investigated as targets for antineoplastic
therapy. Transforming growth factor alpha (TGF-a) can bind
to EGFR and stimulate downstream signaling cascades in-
volved in cell proliferation (Ras/mitogen-activated protein ki-
nase [MAPK]) and antiapoptosis (phosphatidylinositol 3-kinase
[PI3K]/Akt) [7–9]. In addition, the overexpression of TGF-a and
EGFR by many carcinomas correlates with the development of
cancer metastasis, resistance to chemotherapy, and poor
prognosis [9–11]. We have reported that the TGF-a/EGFR
signaling network involving tumor cells and tumor-associated
endothelial cells is a critical component in colon cancer
progression [12].
Vascular endothelial growth factor (VEGF) is one of several
proangiogenic factors whose receptors include VEGFR1 (Flt-1)
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and VEGFR2 (KDR/Flk-1) [13,14]. Hypoxia, an important
stimulus for VEGF production by both normal and tumor
cells, can stimulate the proliferation, differentiation, migra-
tion, and survival of endothelial cells [14]. The expression of
VEGF is substantially increased in solid neoplasms, leading
to an increase in microvascular density and poor prognosis
[15]. VEGF acts not only as a mitogenic and permeability
factor but also as an antiapoptotic survival factor by activat-
ing intracellular signaling such as MAPK and PI3K/Akt path-
ways [16–19]. Therefore, targeting the VEGF and VEGFR
signaling pathways has been undertaken for the treatment
of solid tumors. Several experimental approaches with a
VEGFR tyrosine kinase inhibitor that mimics ATP or antibody
against VEGF have been shown to inhibit angiogenesis and
tumor progression in animal models [20,21].
Tumor cells cannot survive if they lack adequate supplies
of oxygen and nutrients or cannot dispose of toxic molecules.
Oxygen can diffuse from capillaries to a distance of only 150
to 200 mm.When this distance is exceeded, cell death follows
[22–24]. The extent of angiogenesis, however, depends on
the balance between proangiogenic and antiangiogenic fac-
tors released by tumor and host cells [25]. The expression of
epidermal growth factor (EGF), VEGF, or their respective re-
ceptors correlates with angiogenesis and progressive growth
in many human carcinomas [26–31]. The turnover rate of
endothelial cells within these tumor-associated vessels is
20 to 2000 times faster than the rates within the vessels in
normal organs [32]. The proliferation rate of endothelial cells
within the vasculature of normal human organs has been
reported to be < 0.01%, whereas this rate within tumor-
associated vessels has been reported to be 2% to 9% [33].
One recent study reported that tumor-associated vessels ex-
press EGFR and lose ErbB3, whereas normal endothelial
cells express ErbB3 and do not respond to TGF-a [34].
These results suggest that EGFR and VEGFR tyrosine ki-
nase inhibitor is effective for antivascular therapy because
tumor-associated vessels are specifically targeted.
We therefore hypothesized that inhibition of the EGFR and
VEGFR signaling pathways in tumor-associated endothelial
cells of colon tumors inhibits tumor growth. To test this hypoth-
esis, we used SW620 human colon cancer cells [35], which do
not express EGFR, human epidermal growth factor receptor
2 (HER2), or VEGFR, but produce EGF, TGF-a, and VEGF,
which can in turn induce paracrine activation of EGFR and
VEGFR in tumor-associated endothelial cells. We treated nude
mice with oral administrations of 7H-pyrrolo [2,3-d]-pyrimidine
lead scaffold (AEE788), an inhibitor of both EGFR and
VEGFR tyrosine kinases [36], alone or combined with CPT-
11. These treatments produced apoptosis in tumor-associated
endothelial cells and inhibited the progressive growth of
SW620 human colon cancer cells in the cecal wall of the mice.
Materials and Methods
Colon Cancer Cell Line and Culture Conditions
SW620 human colon cancer cells obtained from Dr. Gary
Gallick [35] were maintained in minimal essential medium
supplemented with 10% fetal bovine serum, sodium pyru-
vate, nonessential amino acids, L-glutamine, a 2-fold vita-
min solution (Life Technologies, Grand Island, NY), and a
penicillin/streptomycin mixture (Flow Laboratories, Rockville,
MD). Adherent monolayer cultures were maintained on
plastic and incubated at 37jC in a mixture of 5% CO2 and
95% air. The cultures were free of Mycoplasma and patho-
genic murine viruses (assayed by Science Applications In-
ternational Co., Frederick, MD) and were maintained for no
longer than 12 weeks after recovery from frozen stocks.
In Vivo Selection of Highly Tumorigenic Variants from
the SW620 Human Colon Cancer Cell Line
SW620 cells were injected into the cecal wall of nudemice.
Threemonths after the injection, cecal tumors were harvested
and treated with DNase and collagenase [37,38]. Cells were
established in culture. Primary cultures were passaged in vitro
two or three times and then cells were harvested by trypsini-
zation and injected into the cecum of another set of nudemice.
The selection cycle was repeated two times to yield cell lines
designated SW620CE1 or SW620CE2.
Reagents
AEE788 (synthesized and provided by Novartis Pharma-
ceuticals, Basel, Switzerland) is a low–molecular weight
ATP-competitive dual EGFR and VEGFR tyrosine kinase
family inhibitor [36]. For oral administration (three times
per week), AEE788 was dissolved in DMSO/0.5% Tween
80 and then diluted 1:20 in water. CPT-11 (Camptozar; Eli
Lilly, Indianapolis, IN) was kept at room temperature and
dissolved in 0.9% NaCl on the day of injection.
The following primary antibodies were purchased: rabbit
anti-EGFR (SC03; Santa Cruz Biotechnology, Santa Cruz,
CA); rabbit anti–phosphorylated EGFR (pEGFR) (Tyr1173;
Biosource, Camarillo, CA); rabbit anti-VEGFR2 (Flk-1, C1158;
Santa Cruz Biotechnology); rabbit anti –phosphorylated
VEGFR2 (pVEGFR2) (Flk-1, PC460; Oncogene, Boston,
MA); rabbit anti-VEGFR1 (C17; Santa Cruz Biotechnology);
rabbit anti–mouse F4/80 (MCAP497; Serotec, Raleigh, NC)
and rat anti–mouse CD31 (BD PharMingen, San Diego,
CA) for frozen samples; mouse anti–human TGF-a (GF10;
Oncogene); mouse anti–human VEGF (23071D; BD Phar-
Mingen) and Ki-67 (MIB-1; DakoCytomation, Carpinteria, CA)
for paraffin-embedded samples; and rabbit anti-EGFR (SC03;
Santa Cruz Biotechnology), rabbit anti-pEGFR (Tyr1068;
Cell Signaling Technology, Danvers, MA), and rabbit anti-
VEGFR2 (Flk-1, C1158; Santa Cruz Biotechnology) for West-
ern blot analysis.
The following secondary antibodies were used for colori-
metric immunohistochemical analyses: peroxidase-conjugated
goat anti–rabbit IgG; F(abV)2 (Jackson ImmunoResearch
Laboratories, West Grove, PA); horseradish peroxidase
(HRP)–conjugated donkey anti–sheep IgG (Sigma Chemical
Co., St. Louis, MO); biotinylated goat anti–rabbit IgG (Biocare
Medical, Walnut Creek, CA); streptavidin HRP (Dako); rat
anti–mouse IgG2a HRP (Serotec, Harlan Bioproducts for
Science, Indianapolis, IN); and goat anti–rat HRP (Jackson
ImmunoResearch Laboratories).
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The following fluorescent secondary antibodies were
used: goat anti–rabbit Alexa 488 and goat anti–rat Alexa
594 (both from Molecular Probes, Inc., Eugene, OR). Termi-
nal deoxynucleotidyltransferase–mediated deoxyuridine
5-triphosphate nick-end labeling (TUNEL) staining was done
using a commercial apoptosis detection kit (Promega, Mad-
ison, WI) with modifications.
Western Blot Analysis
Cultures of SW620, SW620CE1, SW620CE2, and KM12C
human colon cancer cells and SKOV3ip1 human ovarian
cancer cells were washed twice with ice-cold phosphate-
buffered saline (PBS); the cells were then scraped into PBS
containing 5 mmol/l EDTA and 1 mmol/l sodium orthovana-
date and centrifuged. The pellet was resuspended in lysis
buffer (20 mmol/l Tris–HCl [pH 8.0], 137 mmol/l NaCl, 10%
glycerol, 2 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl fluo-
ride, 20 mmol/l leupeptin, and 0.15 U/ml aprotinin) and
centrifuged, and the supernatant was collected. The protein
content of the samples was quantified spectrophotometrically.
Aliquots of 30 mg of protein were subjected to electrophoresis
on 7.5% polyacrylamide gels. The protein was then electro-
transferred to nitrocellulose membranes (Millipore, Bedford,
MA). After being blocked with 5% (w/v) nonfat milk in 0.1%
Tween 20 in Tris-buffered saline (20mmol/l Tris–HCl [pH 7.5],
150 mmol/l NaCl, and 0.1% Tween 20), the membranes were
probed with a primary antibody (1:2000 dilution of rabbit anti–
EGFR antibody [Santa Cruz Biotechnology]; 1:1000 dilution
of rabbit anti–pEGFR antibody [Cell Signaling Technology];
1:500 dilution of rabbit anti–VEGFR antibody [Santa Cruz
Biotechnology]; and 1:1000 dilution of rabbit anti–pVEGFR
antibody [Santa Cruz Biotechnology]). The membranes were
then washed and treated with a secondary antibody conju-
gated to HRP (goat anti-rabbit at a 1:3000 dilution [Jackson
ImmunoResearch Laboratories]). Protein bands were visual-
ized using a commercially available chemiluminescence kit
(Amersham Biosciences, Piscataway, NJ).
To evaluate the effect of EGF on the phosphorylation of
EGFR, all tested cell lines were plated onto six-well plates
at a concentration of 3  105 cells/well and incubated for
24 hours. The next day, the cells were transferred to a serum-
free medium and incubated for 24 hours. The cells were then
activated for 15 minutes in the presence or absence of 10 ng/
ml of recombinant human EGF (Santa Cruz Biotechnology)
and then harvested and processed as described above.
Enzyme-Linked Immunosorbent Assay for Human
TGF-a Expression
The level of TGF-a protein in culture supernatants was
determined by using a quantitative immunometric sandwich
enzyme-linked immunosorbent assay kit (Quantikine TGF-a
ELISA kit; R&D Systems, Minneapolis, MN). The absorbance
of the samples was compared with the standard curve.
Reverse Transcriptase–Polymerase Chain
Reaction (RT-PCR)
The expression of EGF-R and VEGFR2 mRNA was
assessed with RT-PCR analysis using 0.5 mg of total RNA
extracted with an RNeasy kit (Qiagen, Hilden, Germany). The
primer sets were as follows: human EGF-R, 5V–TTT-CGA-
TAC-CCA-GGA-CCA-AGC-CAC-AGC-AGG–3V (forward)
and 5V–AAT-ATT-CTT-GCT-GGA-TGC-GTT-TCT-GTA–3V
(reverse); and human VEGFR2, 5V–CAT-CAC-ATC-CAC-
TGG-TAT-T–3V (forward) and 5V–GCC-AAG-CTT-GTA-
CCA-TGT-G–3V (reverse). b-Actin was also amplified for
internal control. PCR products were electrophoresed in 2%
agarose gel and stained with ethidium bromide. The experi-
ment was performed three times.
Effects of AEE788 on Murine Endothelial Cells
To evaluate the effects of AEE788 on the activation of
Akt and extracellular-regulated kinase (ERK) on endothelial
cells, 4  105 murine mesenteric endothelial cells estab-
lished from the ImmortoMouse, as described previously [39]
were seeded into six-well plates in 10% serum-enriched
Dulbecco’s modified Eagle’s medium (DMEM). After 24 hours,
the medium was replaced by serum-free DMEM and the cells
were incubated for another 24 hours. To determine the ef-
fects of AEE788 on the activation of those signaling mole-
cules, the endothelial cells were then pretreated for 1 hour
with AEE788 (1 mM) or vehicle solution. The cells were then
treated with serum-free DMEM or serum-free DMEM con-
taining TGF-a (40 ng/ml), VEGF (40 ng/ml), or a combination
of TGF-a and VEGF for 15 minutes.
Endothelial cells were washed with PBS three times and
cell lysates were collected with 0.1 ml of lysis buffer (50 mM
Tris–HCl [pH 7.5], 50 mM NaCl, 1% Triton X-100, 1 mM
Na3VO4, and protease inhibitors). Proteins were quantified
by the Bicinchoninic Acid Protein Assay Kit (Pierce, Rock-
ford, IL). Western blot analyses were performed as de-
scribed above with 20 mg of proteins. After blocking with
5% (w/v) nonfat dry milk in PBS containing 0.1% Tween-20
(Sigma) for 1 hour, either rabbit anti–ERK1/2 (1:1000 dilu-
tion, catalog #9102; Cell Signaling Technology, Inc.), rabbit
anti–phospho-ERK1/2 (1:1000 dilution, catalog #9101L; Cell
Signaling Technology, Inc.), rabbit anti-Akt (1:1000 dilution,
catalog #9272; Cell Signaling Technology, Inc.), or rabbit
anti–phospho-Akt (1:1000 dilution, catalog #9271L; Cell
Signaling Technology, Inc.) was added and incubated over-
night at 4jC with gentle shaking. Immunodetection was
performed using the horseradish peroxidase–conjugated
secondary antibodies (goat anti-rabbit or goat anti-mouse
at a 1:3000 dilution). Mouse anti-actin (1:10,000 dilution)
was used to confirm the amount of proteins loaded. Protein
bands were visualized using enhanced chemiluminescence
kit (Amersham Biosciences).
Animals and Orthotopic Implantation of Tumor Cells
Male athymic nude mice (NCI-nu) were purchased from
the Animal Production Area of the National Cancer Insti-
tute’s Frederick Cancer Research and Development Cen-
ter (Frederick, MD). The mice were housed and maintained
under specific pathogen-free conditions in facilities approved
by the American Association for Accreditation of Laboratory
Animal Care and in accordance with current regulations
and standards of the U.S. Department of Agriculture, U.S.
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Department of Health and Human Services, and the National
Institutes of Health. The mice were used in accordance with
institutional guidelines when they were 8 to 12 weeks old.
To produce cecal tumors, SW620CE2 cells were har-
vested from subconfluent cultures by a brief exposure to
0.25% trypsin and 0.02% EDTA. Trypsinization was stopped
with a medium containing 10% fetal bovine serum; the cells
were then washed once in a serum-free medium and resus-
pended in Hank’s balanced salt solution. Only suspensions
consisting of single cells with > 90% viability were used. A
total of 5  105 cells in 50 ml of Hank’s balanced salt solution
were injected into the cecal wall of nude mice, as described
previously [12,38].
Treatment of Established Human Colon Carcinoma Tumors
Growing in the Cecum of Athymic Nude Mice
Fourteen days after the cecal injection when tumors were
established, groups of 10 mice each were randomly
assigned to receive one of the following four treatments: 1)
oral administration of water diluted at 1:20 with DMSO/0.5%
Tween 80 (diluent) three times per week and intraperitoneal
(i.p.) injection of PBS once per week (control group); 2)
administration of diluent by oral gavage three times per week
and i.p. injection of 15 mg/kg CPT-11 once per week; 3) oral
gavage of 50 mg/kg AEE788 three times per week and i.p.
injection of PBS once per week; or 4) oral administration of
50 mg/kg AEE788 three times per week and i.p. injection of
15 mg/kg CPT-11 once per week. All treatments were carried
out for 5 weeks.
Necropsy Procedures and Histologic Studies
The mice were euthanized by methoxyflurane, and their
body weight was recorded. On necropsy, tumors growing in
the cecum and peritoneum were excised and weighed. For
immunohistochemical and hematoxylin and eosin staining
procedures, one part of the tumor tissue was fixed in formalin
and embedded in paraffin and another was embedded in
ornithine carbamyl transferase compound (Miles, Elkhart,
IN), rapidly frozen in liquid nitrogen, and stored at 80jC.
All macroscopically enlarged mesenteric lymph nodes were
harvested, and the presence of metastatic disease was
confirmed by histologic examination.
Immunohistochemical Analysis to Detect TGF-a and
VEGF in Tumors
Paraffin-embedded tumors from mice in all treatment
groups were immunostained for expression of TGF-a and
VEGF. The sections were deparaffinized in xylene, treated
with a graded series of alcohol (100%, 95%, and 80%
ethanol/double-distilled water [v/v]), and rehydrated in PBS
at pH 7.5. Endogenous peroxidase was blocked with 3%
hydrogen peroxide in PBS. No antigen retrieval was done.
Samples were exposed to protein blockers (5% normal horse
serum and 1% normal goat serum in PBS) and incubated
overnight at 4jC with each primary antibody at the appropri-
ate dilution. After incubating for 1 hour at room temperature
with peroxidase-conjugated goat anti–rabbit IgG, a positive
reaction was detected by exposing the sample to stable 3,3V-
diaminobenzidine (Open Biosystems, Huntsville, AL) for 5 to
10 minutes. Slides were counterstained with Gill’s hematoxylin.
Immunohistochemical Determination of Ki-67 Antigen
and CD31/Platelet–Endothelial Cell Adhesion
Molecule 1 (PECAM-1) and TUNEL
Paraffin-embedded tissues were used for immunohisto-
chemical identification of Ki-67. Sections were deparaffinized
and rehydrated in PBS, microwaved in water for 5 minutes
for antigen retrieval, incubated at 4jCwith mouse IgG1 anti–
Ki-67 antibody overnight, and incubated for 1 hour at room
temperature with a peroxidase-conjugated rat anti–mouse
IgG1 antibody. Frozen tissues for the identification of CD31/
PECAM-1 were sectioned (8–10 mm), mounted on positively
charged slides, and air-dried for 30 minutes. Frozen sections
were fixed in cold acetone (5 minutes), in acetone/chloroform
(v/v, 5 minutes), and again in acetone (5 minutes) and were
then washed in PBS. Immunohistochemical procedures
were done as described previously [36]. For all parameters,
we used a minimum of six samples.
For the quantification of microvessel density (MVD) in
sections stained for CD31, 10 random 0.159-mm2 fields at
 100 magnification were captured for each tumor, and
microvessels were quantified according to a method de-
scribed previously [10]. For the quantification of the expres-
sion of proliferating cell nuclear antigen, the number of
positive cells was counted in 10 random 0.159-mm2 fields
at  100 magnification.
Analysis of apoptotic cells was done by using a commer-
cially available TUNEL kit (Promega) as described in detail
previously [40]. For immunofluorescence microscopy, we
used an epifluorescence microscope equipped with narrow
band pass excitation filters mounted in a filter wheel (Ludl
Electronic Products, Hawthorne, NY). We captured images
by using a chilled, cooled, charge-coupled device camera
(Photometrics, Tucson, AZ) and SmartCapture software
(Digital Scientific, Cambridge, UK) on a computer (Macin-
tosh; Apple Computer Inc., Cupertino, CA). Images were
further processed with Adobe Photoshop software (Adobe
Systems, Mountain View, CA). To quantify the apoptotic
events, we counted the number of cells undergoing apopto-
sis in 10 random 0.159-mm2 fields at  100 magnification.
Double Immunofluorescence Staining for CD31/PECAM-1
and EGFR, pEGFR, VEGFR, pVEGFR, or TUNEL
Frozen sections of cecal tumors from nude mice were
mounted on slides and fixed. Immunohistochemical proce-
dures for CD31/PECAM-1 were done as described above.
Samples were again blocked briefly in blocking solution (5%
normal horse serum and 1% normal goat serum in PBS) and
incubated at 4jC overnight with antibody against human
EGFR, pEGFR, VEGFR, or pVEGFR. After the samples
were washed in PBS, they were blocked briefly with blocking
solution and incubated with streptavidin–Alexa 488 antibody
for 1 hour. Samples were briefly incubated with Hoechst stain
to visualize the nuclei. Endothelial cells were identified by red
fluorescence, and EGFR, pEGFR, VEGFR, and pVEGFR
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were identified by green fluorescence. The expression of
growth factor receptors or phosphorylated receptors on
endothelial cells was detected by colocalization of red and
green fluorescence, which emitted yellow.
A TUNEL assay was done with the use of a commercial
apoptosis detection kit as described above. TUNEL-positive
apoptotic cells were detected by localized green fluores-
cence within the cell nuclei and endothelial cells were iden-
tified by red fluorescence. Apoptotic endothelial cells were
identified by yellow fluorescence within the nuclei. The total
number of apoptotic cells was quantified in 10 randomly se-
lected microscopic fields and expressed as the ratio of
apoptotic endothelial cells to the total number of endothelial
cells (at  400 magnification).
Statistical Analysis
We used the Mann-Whitney U test to compare the body
weight of mice, tumor weight, the number of Ki-67–positive
cells, the MVD (CD31/PECAM-1), and the number of TUNEL-
positive cells.
Results
Expression of EGFR and VEGFR2 in SW620CE2 Human
Colon Carcinoma Cell Lines Growing in Culture
In the first set of experiments, we examined the expres-
sion of EGFR and VEGFR by SW620CE2 human colon car-
cinoma cells growing in culture. KM12C human colon cancer
cells [38] were used as a positive control for EGFR expres-
sion, and SKOV3ip1 human ovarian carcinoma cells [41]
were used as a positive control for VEGFR2 and HER2
expression. The results of Western blot and RT-PCR anal-
yses are shown in Figure 1. EGFR expression was detected
in KM12C cells but not in SW620CE2 cells; consequently,
the KM12C cells responded to EGF, whereas SW620CE2
Figure 1. Expression of TGF-a, EGFR, VEGFR2, and HER2 by SW620CE2 cells growing in culture. Western blot and RT-PCR analyses reveal that the
SW620CE2 cells do not express (A) EGFR, (B) HER2, or (C) VEGFR2 protein. KM12C human colon cancer cells served as a positive control for EGFR
expression, and SKOV3ip1 human ovarian cancer cells served as a positive control for VEGFR2 and HER2 expression. The SW620CE2 cells produced high levels
of (D) TGF-a but not (E) EGFR or VEGFR2 mRNA.
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cells did not (Figure 1A). HER2 (Figure 1B) or VEGFR2
(Figure 1C) expression was detected in SKOV3ip1 cells
but not in SW620CE2 cells. The SW620 parental and se-
lected variants expressed a high level of TGF-a (Figure 1D).
SW620CE2 cells expressed low levels of EGFR but not
VEGFR2 at the mRNA level (Figure 1E ).
Inhibition of AKT and ERK Activation Pathways by
AEE788 in Murine Colon Endothelial Cells
Murine endothelial cells established from the Immorto-
Mouse were treated with AEE788 (1 mM) or vehicle solution
for 1 hour and then stimulated with serum free DMEM, TGF-
a (40 ng/ml), VEGF (40 ng/ml), or a combination of TGF-a
and VEGF for 15 minutes. Proteins were collected and
Western blot was performed to determine the expression of
phosphorylated Akt and phosphorylated ERK (Figure 2). The
stimulation of endothelial cells with TGF-a significantly in-
creased the phosphorylation of Akt and ERK. Treatment with
VEGF activated Akt but not ERK. The combination of TGF-a
and VEGF produced additive effects on Akt and ERK acti-
vation. Treatment with AEE788 significantly inhibited the
activation of Akt and ERK (Figure 2).
Immunohistochemical Analysis of SW620CE2
Cecal Tumors
In the next set of experiments, we determined the expres-
sion of TGF-a, VEGF, EGFR, pEGFR, VEGFR, pVEGFR, and
HER2 in SW620CE2 cecal tumors by immunohistochemical
analysis. KM12C human colon cancer cells growing in the
cecumof nudemice were used as a positive control for EGFR,
and SKOV3ip1 human ovarian cancer cells growing in the
peritoneal cavity of nude mice were used as a positive con-
trol for VEGFR and HER2. The SW620CE2 cells expressed
TGF-a but not EGFR (Figure 3A). In contrast, KM12C cells
expressed both TGF-a and EGFR (green). Dual localization
of CD31 (red) and EGFR (green) demonstrated that, in both
colon carcinomas, tumor-associated endothelial cells ex-
pressed EGFR and pEGFR (Figure 3A). The SW620CE2 cells
expressed VEGF but did not express VEGFR1 or VEGFR2.
In contrast, the SKOV3ip1 cells expressed both VEGF and
VEGFR2 (green). In both neoplasms, tumor-associated endo-
thelial cells expressed VEGFR2 and pVEGFR2 (Figure 3A).
Dual localization for F4/80 (macrophages marker), CD31
(endothelial cell marker), and VEGFR1 revealed that both
tumor-associated endothelial cells (yellow) and macrophages
(yellow) expressed the VEGFR1 (Figure 3B). In the final set of
immunohistochemical analyses (Figure 3C), we found that
neither the SW620CE2 cells nor the tumor-associated endo-
thelial cells expressed HER2. The SKOV3ip1 cells growing
intraperitoneally but not the tumor-associated endothelial cells
expressed HER2 (positive control).
Treatment of Human Colon Cancer Growing in the
Cecum of Nude Mice
In the next set of experiments, we determined the thera-
peutic effects of AEE788, CPT-11, or the combination of
AEE788 and CPT-11 on the growth of SW620CE2 human
colon cancer cells implanted in the cecum of nude mice.
SW620CE2 cells were injected into the cecal wall of nude
mice. Two weeks later, when the tumors were established
Figure 2. Western blot analysis for expression of phosphorylated Akt and phosphorylated ERK on murine endothelial cells. Murine endothelial cells established
from ImmortoMouse were treated with AEE788 (1 M) or vehicle solution for 1 hour and then stimulated for 15 minutes with serum-free DMEM, TGF-a (40 ng/ml),
VEGF (40 ng/ml), or a combination of TGF-a and VEGF. Stimulation with TGF-a significantly increased the phosphorylation of Akt and ERK on endothelial cells.
Stimulation with VEGF activated Akt but not ERK. The combination of TGF-a and VEGF produced additive activation of Akt and ERK. AEE788 treatment sig-
nificantly inhibited the activation of Akt and ERK.
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(Figure 4), treatment began. Five weeks later, all of the mice
were euthanized and necropsies were performed. In the con-
trol and all three treatment groups, the incidence of cecal
tumors was 100% (Table 1). None of the treatments produced
loss of body weight. Treatment with CPT-11 alone or AEE788
alone significantly inhibited the growth of cecal tumors (P < .01
compared with control group). Treatment with oral adminis-
tration of AEE788 and i.p. injection of CPT-11 produced the
most significant inhibition in tumor growth (P < .001 compared
with control). The gross appearance of the cecal tumors at the
beginning of therapy and after 5 weeks of treatment is shown
in Figure 4. The cecal tumors in control mice and in mice
treated with CPT-11 were well vascularized. In contrast, the
cecal tumors in mice treated with AEE788 alone and in those
treated with AEE788 plus CPT-11 were small without gross
evidence of vascularization.
Cell Proliferation (Ki-67), Apoptosis (TUNEL), and MVD
in Cecal Tumors
Cell proliferation was evaluated by staining for Ki-67 (Fig-
ure 5A). In cecal tumors from control mice, the Ki-67 label-
ing index was 156 ± 25 (Table 2). A significantly lower Ki-67
labeling index was found in tumors from all three treat-
ment groups. The combination of AEE788 and CPT-11 pro-
duced the largest reduction in Ki-67 labeling index, to 65 ± 10
(P < .001).
Figure 3. Immunohistochemical analysis of SW620CE2 cells growing in the cecum of nude mice. Double immunofluorescence staining was used for CD31/
PECAM-1 and EGFR, pEGFR, VEGFR2, or pVEGFR2. (A) The SW620CE2 cells expressed TGF-a and VEGF but not EGFR or VEGFR. The KM12C cells
expressed TGF-a and EGFR (green), and the SKOV3ip1 cells (growing in the peritoneal cavity) expressed VEGF and VEGFR2 (green). In all tumors, the endo-
thelial cells expressed EGFR and VEGFR2 (yellow). (B) Colocalization for VEGFR1 and CD31 (endothelial cells) and F4/80 (macrophages) in SW620CE2 cecal
tumors. (C) Expression of HER2 (green) in SKOV3ipl but not SW620CE2 tumors.
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Themean number of apoptotic tumor cells was determined
by TUNEL staining (Figure 5A). The number of apoptotic
cells in cecal tumors from control mice was 1 ± 1 (Table 2).
Treatment with CPT-11 alone or AEE788 alone increased
the number of apoptotic cells to 9 ± 2 and 15 ± 2, respec-
tively (P < .001). Treatment of mice with both CPT-11 and
AEE788 induced the highest number of apoptotic cells (27 ±
8, P < .001).
The MVD in the cecal tumors was determined by immu-
nohistochemical staining with antibodies against CD31. In
cecal tumors from control mice, the MVD was 49 ± 4 (Fig-
ure 5A and Table 2). Treatment with AEE788 alone de-
creased the MVD to 16 ± 2, and treatment with AEE788
plus CPT-11 decreased the MVD even more, to 10 ± 2
(P < .001).
Immunofluorescence Colocalization for CD31 and TUNEL
To determine whether apoptosis of tumor-associated
endothelial cells preceded the apoptosis of tumor cells, we
examined cecal tumors of mice treated with AEE788 plus
CPT-11 for 2 weeks. Dual localization for CD31/PECAM-1
(red) and TUNEL (green) (Figure 5B) clearly demonstrated
Figure 4. Gross pathology of SW620CE2 tumors in the cecum of nude mice.
Table 1. Therapy for SW620CE2 Tumors Growing in the Cecal Wall of Nude Mice.
Treatment Group Tumor Incidence Body Weight (g), Median (Range) Cecal Tumor Weight (g), Median (Range)
Control 10/10 26.7 (23.6–32.0) 0.15 (0.09–0.33)
CPT-11 (15 mg/kg) 10/10 28.4 (25.7–32.2) 0.09 (0.02–0.18)*
AEE788 (50 mg/kg) 10/10 26.0 (22.7–30.2) 0.05 (0.03–0.06)*
CPT-11 + AEE788 10/10 27.7 (23.4–30.9) 0.02 (0.01–0.05)y
*P < .01 compared with control group.
yP < .001 compared with control group.
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that the majority of TUNEL-positive cells were endothelial
cells (yellow). After 5 weeks of treatment with AEE788 plus
CPT-11, apoptosis of tumor cells was evident (Figure 5A).
Immunohistochemical Analysis of SW620CE2
Cecal Tumors
To determine the biologic effects of treatment with
AEE788 plus CPT-11, cecal tumors were immunohisto-
chemically analyzed for the expression of TGF-a and VEGF.
Treatment with AEE788 alone, CPT-11 alone, or AEE788
Figure 5. Analysis for cell proliferation, apoptosis, and MVD. (A) Cecal tumors from different treatment groups underwent immunohistochemical analysis for the
expression of CD31 (MVD), Ki-67 (cell proliferation), and apoptosis (TUNEL). Note that treatment with AEE788 alone decreased the number of CD31-positive and
Ki-67–positive cells and increased the number of TUNEL-positive cells; these changes were even more pronounced with the combination of AEE788 and CPT-11.
(B) Double immunofluorescence staining was used for CD31/PECAM-1 (red) and TUNEL (green) in cecal tumors from mice treated with AEE788 and CPT-11 for
only 2 weeks. The majority of apoptotic (TUNEL-positive) cells were endothelial cells.
Table 2. Immunohistochemical Analysis of SW620CE2 Tumors Growing in
the Cecal Wall of Nude Mice.
Treatment Group Ki-67* TUNEL* CD31*
Control 56 ± 25 1 ± 1 49 ± 4
CPT-11 (15 mg/kg) 25 ± 16 9 ± 2y 39 ± 6z
AEE788 (50 mg/kg) 82 ± 18y 15 ± 2y 16 ± 2y
CPT-11 + AEE788 65 ± 10y 27 ± 8y 10 ± 2y
*Mean ± SD labeling index.
yP < .001 compared with control (Mann-Whitney U test).
zP < .01 compared with control (Mann-Whitney U test).
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plus CPT-11 did not alter the level of TGF-a (Figure 6A) and
VEGF (Figure 6B) expressed on tumor cells. The expres-
sion of EGF was unaltered (data not shown). We used the
double immunofluorescence staining technique to examine
the expression of EGFR, pEGFR, VEGFR, or pVEGFR by
CD31-positive tumor-associated endothelial cells. Tumor-
associated endothelial cells from all treatment groups
expressed EGFR and VEGFR. However, the phosphoryla-
tion of these receptors in tumor-associated endothelial cells
was inhibited in tumors frommice treated either with AEE788
alone or with AEE788 plus CPT-11 (Figure 6, A and B). The
number and diameter of blood vessels were clearly reduced
in tumors from mice treated with AEE788 alone or AEE788
plus CPT-11 (Figure 6, A and B).
Figure 6. Double immunofluorescence staining for expression of EGFR, pEGFR, VEGFR, or pVEGFR in tumor-associated endothelial cells. (A) Tissue sections
were stained with anti –CD31/PECAM1 antibody (red) and with anti-EGFR, pEGFR, VEGFR, or pVEGFR (green) as described in the Materials and Methods
section. Colocalization of CD31 and EGFR, pEGFR, VEGFR, or pVEGFR appears as yellow fluorescence. Expression of EGFR and VEGFR by tumor-associated
endothelial cells was found in tumors from all treatment groups. Phosphorylation of EGFR and VEGFR on endothelial cells was inhibited by treatment with AEE788
or AEE788 plus CPT-11. Note that treatment with AEE788 alone decreased the number and diameter of blood vessels and that this effect was even more
pronounced with combined AEE788 and CPT-11.
Antivascular Therapy for Colon Cancer with AEE788 Sasaki et al. 1075
Neoplasia . Vol. 9, No. 12, 2007
Discussion
Our results demonstrate that, in colon carcinoma growing in
the cecum of nude mice, pEGFR and pVEGFR on tumor-
associated endothelial cells (and not on tumor cells) are the
primary targets for therapy by AEE788, a tyrosine kinase
inhibitor of both receptors. Previous studies from our labo-
ratory revealed that the expression of pEGFR [12,40–43],
pVEGFR [42–45], and platelet-derived growth factor recep-
tor [45–47] on tumor-associated endothelial cells is depen-
dent on the production of the relevant ligands by adjacent
tumor cells. Moreover, targeting the tyrosine kinase recep-
tors on tumor-associated endothelial cells resulted in a
treatment for human renal cancer in the kidneys of nude
mice [48] and for multidrug-resistant human prostate cancer
in the prostate of nude mice [46].
The survival of all cells in the body depends on an
adequate supply of oxygen and nutrients. The proliferation
of tumor cells and the expansion of the tumor mass therefore
require a new blood supply, i.e., angiogenesis [26,49]. The
expression of EGF and VEGF and the activation of their
respective receptors have been shown to correlate with
angiogenesis and the progressive growth of human colon
carcinoma [12]. Moreover, the activation of tyrosine kinase
receptors on tumor-associated endothelial cells was reported
to increase their resistance to anticycling chemotherapeutic
agents [50]. Taken together, these findings suggest that the
inhibition of EGFR and VEGFR signaling on tumor-associated
endothelial cells in combination with an appropriate chemo-
therapeutic drug induces apoptosis of endothelial cells, lead-
ing to apoptosis of the surrounding tumor cells and stromal
cells and thereby to the control of tumor growth.
Because EGFR and VEGFR are expressed on both tumor
cells and tumor-associated endothelial cells, we carried out
the present studies with SW620CE human colon cancer cells
that do not express EGFR, HER2, VEGFR1, or VEGFR2
(Figures 1 and 3). These cells, however, produce TGF-a and
VEGF in culture (Figure 1) and in vivo (Figure 3), and these
ligands phosphorylate the respective receptors on tumor-
associated endothelial cells in a paracrine manner (Figures 3
and 6). The inhibition of pEGFR and pVEGFR resulting in
targeted therapy is therefore restricted to tumor-associated
endothelial cells, and this orthotopic model for colon cancer
is ideally suited to test our hypothesis.
In all in vivo studies, treatment began 2 weeks after the
implantation of SW620CE2 cells into the cecum of nude mice,
which produced well-established tumors (Figure 4). Blockade
of the EGFR and VEGFR signaling pathways by the oral ad-
ministration of the tyrosine kinase inhibitor AEE788 in combi-
nation with i.p. injections of CPT-11 inhibited further growth
of these neoplasms. The major signaling pathways induced
by the activation of tyrosine kinase receptors are MAPK and
PI3K, which affect cell proliferation and inhibition of apoptosis
[50–55]. In our studies, the administration of AEE788 or
AEE788 plus CPT-11 inhibited the phosphorylation of EGFR
and VEGFR on tumor-associated endothelial cells. Apoptosis
of endothelial cells in the tumor vasculature was evident within
1 to 2 weeks of therapy (Figure 5B). Continued treatment with
AEE788 plus CPT-11 led to a marked decrease in MVD, de-
creased the proliferation of tumor cells, and increased apop-
tosis of tumor cells (Figure 5A).
In conclusion, EGFR and VEGFR signaling in tumor-
associated endothelial cells is an important regulator of colon
cancer progression. Abrogating the signaling activation by
a dual tyrosine kinase inhibitor in combination with conven-
tional chemotherapy can induce significant apoptosis of
tumor-associated endothelial cells leading to apoptosis of
tumor cells. These data generated with tumor cells that
do not express the EGFR, HER2, or VEGFR clearly indi-
cate that targeting EGFR and VEGFR signaling in tumor
vasculature provides a new approach to the treatment of
colon cancer.
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